NeRRe Therapeutics Ltd.

NeRRe Therapeutics Ltd. , based in the UK, specializes in developing innovative treatments targeting cough hypersensitivity disorders, focusing on its flagship product, orvepitant. Founded in 2012, NeRRe Therapeutics Ltd. is dedicated to developing therapeutic solutions for cough hypersensitivity disorders.

The company has completed 3 deals, with its most recent funding round occurring on June 25, 2021. This Series B round raised GBP 20. 50 million, with prominent investors including Advent Life Sciences, Columbus Venture Partners, Forbion, Fountain Healthcare Partners, OrbiMed Advisors, and The Future Fund. The current CEO is Mary Kerr, while Mike Trower is the founder.

NeRRe Therapeutics specializes in the development of orvepitant, a neurokinin (NK)-1 receptor antagonist designed as a first-in-class, once-daily oral treatment targeting cough hypersensitivity disorders. The primary indication for orvepitant is chronic cough associated with idiopathic pulmonary fibrosis (IPF), a serious lung condition characterized by a persistent and often disabling cough that is resistant to existing medical therapies. NeRRe aims to address the unmet need in managing cough related to terminal diseases, particularly since IPF is recognized as an orphan disease in Europe and the USA. The product is expected to serve patients suffering from refractory cough, with its potential market reach extending across Europe and the United States.

NeRRe Therapeutics has structured its business model around partnerships and collaborations, which are essential for advancing its clinical asset, orvepitant. Revenue generation is expected through licensing agreements with larger pharmaceutical companies and milestone payments linked to the success of clinical trials. Given the company's focus on a niche market, transactions may involve collaborations with healthcare providers managing chronic cough conditions, facilitating access to their treatment offerings. The company reported an EBITDA of GBP -7,787,209.

50 for the most recent year in 2023. Following the successful Series B funding round on June 25, 2021, where GBP 20. 50 million was raised, NeRRe Therapeutics plans to utilize this capital to further develop its clinical treatment, orvepitant. The company is focused on launching this innovative product while also exploring opportunities for expansion into new geographical markets, particularly in Europe and the United States, by the end of 2023.

These initiatives will be critical in establishing NeRRe's presence in the market and addressing patient needs in cough management.